mProX™ Human RPS6KA2 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1222-KX482	Magic™ Human RSK3(RPS6KA2) in Vitro Assay	Human		Kinase Assay

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;SK-OV-3;OVCAR-3

Target Classification

Kinase Cell Lines

Target Research Area

Pain and Addiction Research

Related Diseases

Coffin-Lowry Syndrome

Gene ID

Human:6196

UniProt ID

Human:Q15349

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

RPS6KA2, also known as ribosomal protein S6 kinase A2, has been studied in various contexts. In ovarian cancer, RPS6KA2 is involved in cuproptosis, a form of programmed cell death, and its related long non-coding RNAs (lncRNAs) have been characterized. These lncRNAs have been used to define molecular subtypes of ovarian cancer and establish a prognostic signature that can predict survival time, immune characteristics, and response to therapy. In Crohn's disease, RPS6KA2 is associated with DNA methylation alterations that may predict disease recurrence following intestinal resection. In knee osteoarthritis, RPS6KA2 enhances the chondrogenic differentiation of induced mesenchymal stem cells (iMSCs), leading to articular cartilage regeneration. In Yorkshire pigs, RPS6KA2 is one of the candidate genes identified in a genome-wide association study on reproductive traits. Finally, in food allergy, epigenome-wide association studies have found DNA methylome variations in RPS6KA2 and other genes associated with immune responses and regulatory T cell function. These findings provide insights into the role of RPS6KA2 in different diseases and highlight its potential as a therapeutic target or biomarker.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human RPS6KA2 Stable Cell Line (S01YF-1023-PY93). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Casey Miller (Verified Customer)

What is the role of RPS6KA2 in osteosarcoma? Aug 04 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

Downregulation of RPS6KA2 is associated with the inhibition of osteosarcoma proliferation, suggesting its potential as a therapeutic target. Aug 04 2023

chat Jordan Brown (Verified Customer)

How does RPS6KA2 affect ovarian cancer? Jan 09 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

Low expression of RPS6KA2, mediated by specific ncRNAs, can influence the proliferation of ovarian cancer cells via the p38/MAPK signaling pathway. Jan 09 2022

Published Data

Fig.1 The proliferation of ovarian cancer cells was inhibited by RPS6KA2.

In the investigation of the inhibitory effects of RPS6KA2 on ovarian cancer cell proliferation, a CCK-8 assay was carried out. It was observed that in comparison to the control cells, a reduction in cell viability of ovarian cancer cells was induced by the OE group of OVCAR3 cells. Conversely, the proliferation of ovarian cancer cells was promoted when SKOV3 cells were transfected with RPS6KA2 shRNA.

Ref: Fu, Zhiqin, et al. "ncRNAs mediated RPS6KA2 inhibits ovarian cancer proliferation via p38/MAPK signaling pathway." Frontiers in Oncology 13 (2023): 1028301.

Pubmed: 36741009

DOI: 10.3389/fonc.2023.1028301

Research Highlights

Li, Nan. et al. "Molecular Characterization of Cuproptosis-related lncRNAs: Defining Molecular Subtypes and a Prognostic Signature of Ovarian Cancer." Biological trace element research, 2023.
A recently discovered form of programmed cell death known as Cuproptosis has been found to be altered in women with ovarian cancer. In order to further understand the effects of Cuproptosis on ovarian cancer, researchers conducted a study using data from various databases and analyzed the expression of specific genes and long non-coding RNAs (lncRNAs). Through their analysis, the researchers were able to identify four molecular subtypes of ovarian cancer based on Cuproptosis-related lncRNAs, which differed in survival time, immune characteristics, and somatic mutation. Furthermore, a prognostic signature consisting of 10 lncRNAs was established and found to be significantly correlated with prognosis, immune microenvironment, and response to certain treatments. Additional experiments on different ovarian cancer cell lines also supported the potential role of these lncRNAs in tumor growth and response to treatment. This study sheds light on the heterogeneity of ovarian cancer and offers new insights on its prognosis and immune microenvironment, with potential clinical benefits for patients.
Li, Nan. et al. "Molecular Characterization of Cuproptosis-related lncRNAs: Defining Molecular Subtypes and a Prognostic Signature of Ovarian Cancer." Biological trace element research, 2023.
Pubmed: 37528285 DOI: 10.1007/s12011-023-03780-3

T Ventham, Nicholas. et al. "Genome-Wide Methylation Profiling in 229 Patients With Crohn's Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn's Disease (TOPPIC)." Cellular and molecular gastroenterology and hepatology, 2023.
The study focuses on the potential role of DNA methylation alterations in gene-environment interaction in diverse health conditions, including cancer, aging, and inflammatory bowel disease (IBD). The researchers aim to investigate whether changes in the DNA methylome of patients undergoing surgery can predict the recurrence of Crohn's disease (CD) after intestinal resection. Additionally, they plan to compare the circulating methylome of patients with established CD with that reported in previous studies involving inception cohorts.
T Ventham, Nicholas. et al. "Genome-Wide Methylation Profiling in 229 Patients With Crohn's Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn's Disease (TOPPIC)." Cellular and molecular gastroenterology and hepatology, 2023.
Pubmed: 37331566 DOI: 10.1016/j.jcmgh.2023.06.001